636
Participants
Start Date
April 30, 2008
Primary Completion Date
April 30, 2009
Study Completion Date
October 31, 2009
pramlintide acetate
subcutaneous injection, twice a day
metreleptin
subcutaneous injection, twice a day
placebo-P
subcutaneous injection, twice a day
placebo-M
subcutaneous injection, twice a day
Research Site, Birmingham
Research Site, Chandler
Research Site, Santa Rosa
Research Site, Walnut Creek
Research Site, Denver
Research Site, Jacksonville
Research Site, Miami
Research Site, Pembrook Pines
Research Site, Plantation
Research Site, Atlanta
Research Site, Chicago
Research Site, Springfield
Research Site, Overland Park
Research Site, Baton Rouge
Research Site, Auburn
Research Site, Boston
Research Site, Edina
Research Site, St Louis
Research Site, Butte
Research Site, New York
Research Site, Statesville
Research Site, Cincinnati
Research Site, Columbus
Research Site, Eugene
Research Site, Medford
Research Site, Anderson
Research Site, Greer
Research Site, Mt. Pleasant
Research Site, Nashville
Research Site, Austin
Research Site, Dallas
Research Site, San Antonio
Research Site, Salt Lake City
Research Site, Norfolk
Research Site, Belingham
Research Site, Olympia
Lead Sponsor
AstraZeneca
INDUSTRY